analytical-chemistry
(3)
Huafen Liu Built the Missing Middle of Clinical Mass Spectrometry
After two decades inside Pfizer, Roche and SCIEX, Huafen Liu left the multinational track to solve an unglamorous problem: making an exacting laboratory craft work the same way, every day. Her answer was not one machine, but a system around the machine.
Olivier Roux Spent Two Decades Learning What Molecules Refuse to Do
Before Olivier Roux sold manufacturing partnerships, he validated methods, managed reference standards and wrestled with process details. His career is a case study in how technical depth becomes commercial judgment.
Todd Dickinson
Todd Dickinson is the CEO and a board member of Stellaromics, a Boston biotech commercializing 3D spatial biology born from Karl Deisseroth's Stanford lab and Xiao Wang's work at MIT and the Broad Institute. A Tufts-trained analytical chemist who did his PhD under David Walt, he spent more than 20 years turning genomics inventions into products: over a decade at Illumina during its rise as the DNA-sequencing leader, commercial work on Bionano Genomics' Irys nanochannel arrays, and CEO stints at Dovetail Genomics and Arc Bio, which he merged into Cantata Bio in 2022. At Stellaromics he raised $80 million in Series B (led by Catalyst4 with Stanford University Ventures) to launch Pyxa, the first commercial platform that reads gene expression inside intact tissue up to 40x thicker than conventional methods.